Abstract
Introduction: The therapeutic strategy for metastatic colorectal cancer (mCRC) has evolved greatly in the last two decades. This study aimed to compare patients with mCRC treated at the University Hospital of Sousse (Tunisia) through three periods, in terms of treatment strategy; objective response rate (ORR) to chemotherapy; median overall survival (OS) and prognostic factors conditioning OS. Methods: This was a retrospective study covering the period from January 1994 to December 2011. It involved 401 patients with mCRC divided into three groups: group 1 (G1) including patients treated in the period 1994-1998, group 2 (G2) including patients treated in the period 1999-2005 and group 3 (G3) including patients treated in the period 2006-2011. Results: The ORR after 3 cycles of first line chemotherapy was 33%, 50% and 57.8% for G1, G2 and G3 respectively. The median OS was 13.8 months for G1, 19 months for G2 and 23 months for G3. The prognostic factors associated with a better OS for G3 were absence of initial tumor complication, normal initial level of carcinoembryonic antigen, normal liver function tests, surgery of the primary tumor, surgery of liver metastases and the ORR after three cycles of first line chemotherapy. Conclusion: The development of the therapeutic strategy, whatever of medical or surgical nature, has led to improved response rates and survival of patients treated for mCRC.
Highlights
The therapeutic strategy for metastatic colorectal cancer has evolved greatly in the last two decades
We divided the 401 patients into three groups: group 1 (G1) including patients treated in the period 1994-1998, group 2 (G2) including patients treated in the period 1999-2005 and group 3 (G3) including patients treated in the period 2006-2011
According to these dates and practice findings, we considered that the G1 patients were treated mainly with 5FU, the G2 patients were treated mainly with irinotecan and G3 patients were treated with oxaliplatine and to lesser extent with bevacizumab
Summary
The therapeutic strategy for metastatic colorectal cancer (mCRC) has evolved greatly in the last two decades. The median survival of mCRC patients treated with chemotherapy including 5-Fluoro Uracil (5-FU) was between 6 and 12 months [2], while this median survival after introduction of oxaliplatin, irinotecan and targeted therapies was prolonged up to 30 months, or even more with personalized targeted therapies based on the molecular profile of the tumor [3]. To our knowledge, this evolution has not been assessed over a long period in a same center and such evaluation would give a better idea about the progress resulting from therapeutic advances
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
